Overview

Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks

Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a 12-week study of oral tolfenamic acid vs. placebo in Progressive Supranuclear Palsy (PSP)
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
NeuroTau, Inc.
Collaborator:
The Cleveland Clinic
Treatments:
Tolfenamic acid